Merck gets approval for its CRISPR genome-editing technology in China
Category: #health  By Saipriya Iyer  Date: 2018-04-24
  • share
  • Twitter
  • Facebook
  • LinkedIn

Merck gets approval for its CRISPR genome-editing technology in China

Merck KGaA has declared that the Chinese Patent Office has provided it with the right to use its CRISPR gene-editing technology in the country. According to the company’s statement, the CRISPR technique helps chromosomes to alter in the living cells and is one of the modern therapies that can be used for treating many of the chronic disorders.

The firm also seems to have added that the new technology is used to determine the genes associated with cancer along with other rare ailments including reverse mutations causing blindness in the individuals. Udit Batra, CEO of Life Sciences division at Merck KGaA, has stated that the firm will license its CRISPR-linked patents to companies involved in carrying out pure scientific research activities, offering therapeutic solutions, and making use of farming technology.

As per reliable sources, Merck has filed patents for using its CRISPR technology across countries such Japan, Brazil, U.S., and India. Regions such as South Korea, Israel, Australia, Canada, Europe, and Singapore have already approved the patents for the use of CRISPR technology for treating various diseases. The firm’s forthcoming CRISPR technology patent in China includes chromosomal integration or cutting sequence of chromosomes from the eukaryotic cell tissues along with the insertion of donor DNA sequence into these Eukaryotic cells by using the gene-editing CRISPR technique.

The genome-editing technology assists the researchers to replace disease linked gene mutation with a beneficial DNA gene sequence. Merck has claimed that the CRISPR gene-editing technology can be utilized to add transgenes to the endogenous protein materials, helping them in visual tracking of the disease within the cells.

The firm, which is involved in both the deployment and supply of the genome editing CRISPR Technology, holds the view that the new technique has resulted in many of the technological breakthroughs witnessed lately across the medical and biotechnology sectors. Apparently, Merck supports the gene-editing applications and complies with the ethical & legal standards that regulate gene-editing technology.



About Author

Saipriya Iyer

Email: [email protected]   

Saipriya Iyer

Saipriya Iyer develops content for Market Size Forecasters, Algosonline, and myriad other platforms. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her bel...

Read More

More News By Saipriya Iyer

DTE Energy pledges to reach net-zero emissions of GHG by 2050
DTE Energy pledges to reach net-zero emissions of GHG by 2050
By Saipriya Iyer

DTE Energy has reportedly pledged to reach the net-zero GHG (greenhouse gas) emissions by 2050. This can be ensured through various actions involving customers, suppliers, and its infrastructure, that align with the lo...

Researchers investigate a novel treatment for Childhood Alzheimer’s
Researchers investigate a novel treatment for Childhood Alzheimer’s
By Saipriya Iyer

Researchers at the Lundquist Institute have reportedly collaborated with the Cure Sanfilippo Foundation on a new clinical trial to investigate if repurposing an anti-inflammatory drug could provide relief to children t...

Amazon unveils $2 billion climate fund to help decarbonize economies
Amazon unveils $2 billion climate fund to help decarbonize economies
By Saipriya Iyer

Amazon, the renowned technology and online retail giant, has reportedly announced a new initiative that would help efforts to develop sustainable technologies, products, and services that would allow Amazon and several...